Clinical Trials Browser

Active not recruiting × Neoplasms × pomalidomide × Clear all

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT06924424 2025-04-11

Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

Phase NA Active not recruiting

Multiple Myeloma, Neoplasms